Rafael Holdings, Inc. (RFL)
Rafael Holdings, Inc. operates in the Real Estate - Services industry of the Real Estate sector, headquartered in Newark, NJ, US. The stock last traded at $2.01, up 4.53% on the session, giving a market capitalisation of $102.8M. On trailing twelve-month figures it carries a trailing P/E of -2.94, a net margin of -3321.7%. Its beta of 0.33 implies it has historically moved less than the broad market.
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Rafael Holdings, Inc. is most often compared with the following Real Estate names: